469 related articles for article (PubMed ID: 23360763)
1. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
2. Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.
Cozza G; Girardi C; Ranchio A; Lolli G; Sarno S; Orzeszko A; Kazimierczuk Z; Battistutta R; Ruzzene M; Pinna LA
Cell Mol Life Sci; 2014 Aug; 71(16):3173-85. PubMed ID: 24442476
[TBL] [Abstract][Full Text] [Related]
3. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
4. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
[TBL] [Abstract][Full Text] [Related]
5. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
[TBL] [Abstract][Full Text] [Related]
7. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
8. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
9. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
[TBL] [Abstract][Full Text] [Related]
10. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
11. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Mariano M; Hartmann RW; Engel M
Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
[TBL] [Abstract][Full Text] [Related]
12. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
13. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
14. Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase Rio1.
Kubiński K; Masłyk M; Orzeszko A
Mol Cell Biochem; 2017 Feb; 426(1-2):195-203. PubMed ID: 27909846
[TBL] [Abstract][Full Text] [Related]
15. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
López-Ramos M; Prudent R; Moucadel V; Sautel CF; Barette C; Lafanechère L; Mouawad L; Grierson D; Schmidt F; Florent JC; Filippakopoulos P; Bullock AN; Knapp S; Reiser JB; Cochet C
FASEB J; 2010 Sep; 24(9):3171-85. PubMed ID: 20400536
[TBL] [Abstract][Full Text] [Related]
16. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
17. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
[TBL] [Abstract][Full Text] [Related]
18. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.
Cozza G; Zanin S; Sarno S; Costa E; Girardi C; Ribaudo G; Salvi M; Zagotto G; Ruzzene M; Pinna LA
Biochem J; 2015 Nov; 471(3):415-30. PubMed ID: 26349539
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
20. Peptide biosensors for the electrochemical measurement of protein kinase activity.
Kerman K; Song H; Duncan JS; Litchfield DW; Kraatz HB
Anal Chem; 2008 Dec; 80(24):9395-401. PubMed ID: 18989981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
